CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Flecainide Acetate +2 moredrug
Likely dose
Flecainide Acetate 0.8 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01117454
NCT01117454N/ACompleted
CompareCT.gov

A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

Vanderbilt University Medical Center·interventional·Posted May 5, 2010·Updated Jun 14, 2017

In Brief

A clinical study evaluating Flecainide Acetate, Placebo, and 1 other intervention for Catecholaminergic Polymorphic Ventricular Tachycardia. Completed, enrolled 14 participants across 10 sites.

Detailed Summary

The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCatecholaminergic Polymorphic Ventricular Tachycardia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 5, 2010
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.2 years ago

Interventions

Flecainide Acetatedrug

oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

Placebodrug

placebo, similar in appearance to flecainide

Beta blockerdrug

Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.